| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 15.49 | 19.3 | 45.22 | 4.05 |
Op profit growth | -24.63 | 66.94 | 31.91 | 6.2 |
EBIT growth | -25.79 | 82.59 | 34.54 | 4.61 |
Net profit growth | -26.87 | 98.31 | 71.79 | 0.61 |
Profitability ratios (%) | ||||
OPM | 13.23 | 20.28 | 14.49 | 15.95 |
EBIT margin | 11.68 | 18.18 | 11.87 | 12.82 |
Net profit margin | 8.23 | 13.01 | 7.82 | 6.61 |
RoCE | 19.42 | 31.8 | 19.46 | 15.67 |
RoNW | 5.25 | 8.95 | 6.38 | 4.81 |
RoA | 3.42 | 5.69 | 3.2 | 2.02 |
Per share ratios (₹) | ||||
EPS | 22.14 | 30.09 | 60.69 | 34.9 |
Dividend per share | 1 | 2.5 | 2 | 1 |
Cash EPS | 16.73 | 24.73 | 39.76 | 17.91 |
Book value per share | 111.91 | 98 | 280.03 | 193.12 |
Valuation ratios | ||||
P/E | 19.37 | 23.09 | 2.08 | 3.62 |
P/CEPS | 25.63 | 28.08 | 3.18 | 7.07 |
P/B | 3.83 | 7.08 | 0.45 | 0.65 |
EV/EBIDTA | 13.18 | 15.43 | 5.92 | 8.7 |
Payout (%) | ||||
Dividend payout | 0 | 0 | 0 | 0 |
Tax payout | -24.06 | -24.02 | -24.27 | -33.89 |
Liquidity ratios | ||||
Debtor days | 95.7 | 88.41 | 87.26 | 98.57 |
Inventory days | 69 | 62.7 | 60.99 | 71.58 |
Creditor days | -67.5 | -70.07 | -69.52 | -79.57 |
Leverage ratios | ||||
Interest coverage | -14.01 | -17.06 | -6.36 | -4.56 |
Net debt / equity | 0.5 | 0.37 | 0.58 | 1.19 |
Net debt / op. profit | 1.57 | 0.78 | 1.45 | 2.73 |
Cost breakup (₹) | ||||
Material costs | -66.86 | -60.28 | -64.18 | -61.67 |
Employee costs | -3.32 | -3.73 | -3.84 | -4.65 |
Other costs | -16.57 | -15.69 | -17.47 | -17.7 |
The consolidated net profit of the company increased 1.1% YoY at ₹37.1 crore from ₹36.7 crore that was reported for the same quarter last year.
Aarti Drugs shares has witnessed a 8% dip in the last one year, and 10% dip in the last six months.
Here are some of the stocks that may see significant price movement today: Avenue Supermarts, Bank of Baroda, HDFC Bank, etc.
Here are some of the stocks that may see significant price movement today: HFCL, Aster DM Healthcare, Tata Steel, Glenmark Pharma, etc.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
